Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya

• Philip Bejon ,

  *To whom correspondence should be addressed. E-mail: pbejon@well.ox.ac.uk

  Affiliation Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya

  ⨯
• Edna Ogada,

  Affiliation Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya

  ⨯
• Tabitha Mwangi,

  Affiliations Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom

  ⨯
• Paul Milligan,

  Affiliation London School of Hygiene and Tropical Medicine, London, United Kingdom

  ⨯
• Trudie Lang,

  Affiliation Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom

  ⨯
• Greg Fegan,

  Affiliations Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya, London School of Hygiene and Tropical Medicine, London, United Kingdom

  ⨯
• Sarah C. Gilbert,

  Affiliation Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom

  ⨯
• Norbert Peshu,

  Affiliation Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya

  ⨯
• Kevin Marsh,

  Affiliations Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya, Nuffield Department of Clinical Medicine, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom

  ⨯
• Adrian V.S. Hill

  Affiliations Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom

  ⨯